# Phil Vickers

> Phil Vickers is President and CEO of Solu Therapeutics, a Boston clinical-stage biotech building small-molecule 'chimeras' that ferry cytotoxic payloads to disease-driving cells. He arrived in September 2023 after runs at Faze Medicines and Northern Biologics, and R&D leadership at Shire, Boehringer-Ingelheim, Pfizer and Merck. In April 2025 he closed a $41M Series A with Eli Lilly, Pappas Capital and the Leukemia & Lymphoma Society and dosed the first patient in a Phase 1 trial of STX-0712 for CMML.

- **Role:** President and CEO at Solu Therapeutics
- **Organizations:** Solu Therapeutics, AVROBIO (board), PTEN Research (SAB)
- **Education:** Ph.D., Biochemistry, University of Toronto, Postdoctoral fellowship, National Cancer Institute, Bethesda MD
- **Known for:** Closed $41M Series A for Solu Therapeutics in April 2025 with Eli Lilly, Pappas Capital, Biovision Ventures, Hengdian Group Capital and the Leukemia & Lymphoma Society TAP, Advanced Solu from seed-stage to clinical-stage in under two years, First patient dosed with STX-0712 in Phase 1 trial for CMML

## Career timeline

- **early career** — Senior biologist, Merck Research Laboratories
- **~13 years** — Pfizer, rising to Vice President, Research
- **post-Pfizer** — SVP and US Head of Research, Boehringer-Ingelheim
- **later** — Chief Scientific Officer, Resolvyx Pharmaceuticals
- **later** — Global Head of R&D and Executive Leadership Team member, Shire Pharmaceuticals
- **later** — President and CEO, Northern Biologics
- **prior** — President and CEO, Faze Medicines
- **2023-09** — Appointed President and CEO, Solu Therapeutics
- **2024-08** — Solu accepted into Lilly Gateway Labs, Boston
- **2025-04** — Closes $41M Series A; first patient dosed in Phase 1 of STX-0712 for CMML

## Achievements

- Closed $41M Series A for Solu Therapeutics in April 2025 with Eli Lilly, Pappas Capital, Biovision Ventures, Hengdian Group Capital and the Leukemia & Lymphoma Society TAP
- Advanced Solu from seed-stage to clinical-stage in under two years
- First patient dosed with STX-0712 in Phase 1 trial for CMML
- Former Global Head of R&D at Shire Pharmaceuticals
- Led two prior venture-backed biotechs as CEO (Northern Biologics, Faze Medicines)

## Latest updates

- **2025-04** — Solu closes $41M Series A led by new investors including Eli Lilly; first patient dosed in Phase 1 trial of STX-0712 for CMML.
- **2024-08** — Solu accepted into Lilly Gateway Labs in Boston.
- **2023-09** — Appointed President and CEO of Solu Therapeutics.

## Links

- Website: https://solutherapeutics.com
- LinkedIn: https://www.linkedin.com/in/phil-vickers-a4a4b88

---

Profile page: https://yespress.io/phil-vickers
Published by YesPress — https://yespress.io
Last updated: 2026-07-08